Lipcut (Simvastatin)

Simvastatin is converted in the liver to its active form, which inhibits the enzyme HMG‑CoA reductase. This blockage reduces the synthesis of cholesterol inside liver cells, leading to increased expression of LDL receptors and enhanced removal of LDL cholesterol from the bloodstream.

The appropriate dose of Lipcut is determined by the prescribing clinician based on the patient’s cholesterol levels, overall cardiovascular risk, age, and any co‑existing medical conditions. Dosage adjustments are made according to clinical response and tolerability.

Simvastatin is generally contraindicated during pregnancy because cholesterol synthesis is essential for fetal development. It should only be used in breastfeeding women if the potential benefit justifies the potential risk to the infant, and this decision must be made by a qualified healthcare professional.

To order Lipcut, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control), and necessary import documentation.

Lipcut (simvastatin) is a moderately potent statin with a well‑established efficacy profile. Compared with higher‑intensity statins such as atorvastatin or rosuvastatin, simvastatin may achieve slightly lower LDL‑C reductions at equivalent doses, but it remains a cost‑effective option for many patients when prescribed at appropriate strengths.

Lipcut tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lipcut is taken orally, usually once daily in the evening, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew it unless specifically instructed.

The most serious adverse effects of Lipcut include rhabdomyolysis, a severe form of muscle breakdown that can lead to kidney failure, and significant liver injury. Patients should promptly report unexplained muscle pain, weakness, or dark urine, and clinicians should monitor liver enzymes regularly.

Lipcut should not be used by individuals with active liver disease, unexplained persistent elevations of hepatic transaminases, or a known hypersensitivity to simvastatin or any of its excipients. It is also contraindicated in patients taking certain contraindicated medications, such as strong CYP3A4 inhibitors, without appropriate dose adjustments.